DeepMed Research

Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Phase 2

Active, not recruiting

Conditions: Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Durvalumab
Drug: carboplatin
Drug: etoposide
Radiation: Thoracic radiotherapy

First Posted Date: 2020-07-16

Last Posted Date: 2023-09-13

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 46

Registration Number: NCT04472949

Locations: 🇨🇭
Spital Männedorf, Männedorf, Switzerland
🇨🇭
Regionalspital Thun, Thun, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland

and more 11 locations

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer
NSCLC

Interventions: Drug: Durvalumab
Radiation: Radiotherapy

First Posted Date: 2020-01-29

Last Posted Date: 2025-03-13

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 90

Registration Number: NCT04245514

Locations: 🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany
🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland

and more 10 locations

Prostate Cancer Biobank

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Other: Observation

First Posted Date: 2019-07-18

Last Posted Date: 2022-06-08

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 1323

Registration Number: NCT04024475

Locations: 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Kantonsspital Olten, Olten, Switzerland

and more 9 locations

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: IP-001
Device: Thermal Ablation

First Posted Date: 2019-06-21

Last Posted Date: 2025-03-18

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 28

Registration Number: NCT03993678

Locations: 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Kantonsspital Graubünden, Chur, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Phase 2

Active, not recruiting

Conditions: Testicular Cancer
Seminoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2019-05-06

Last Posted Date: 2025-01-16

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 135

Registration Number: NCT03937843

Locations: 🇨🇭
Kantonsspital Graubünden, Chur, Switzerland
🇨🇭
Hopital de Sion, Sion, Switzerland
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

and more 16 locations

Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Radical prostatectomy (RP) followed by ePLND
Procedure: Radical prostatectomy (RP) only

First Posted Date: 2019-04-19

Last Posted Date: 2023-03-09

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 57

Registration Number: NCT03921996

Locations: 🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland

and more 8 locations

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Other: Mono-chemotherapy
Other: Endocrine-Therapy

First Posted Date: 2019-04-05

Last Posted Date: 2021-06-16

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 25

Registration Number: NCT03905343

Locations: 🇧🇪
Grand Hôpital de Charleroi, Charleroi, Belgium
🇧🇪
Jessa Ziekenhuis, Hasselt, Belgium
🇨🇭
Brustzentrum Basel - Praxis für ambulante Tumortherapie, Basel, Switzerland

and more 31 locations

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Phase 1

Terminated

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Copanlisib
Drug: Venetoclax

First Posted Date: 2019-03-22

Last Posted Date: 2022-04-01

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 7

Registration Number: NCT03886649

Locations: 🇨🇭
Universitaetsspital Basel, Basel, Switzerland
🇨🇭
Hôpitaux Universitaires de Genève, Genève, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland

and more 3 locations

Activity Program During Aromatase Inhibitor Therapy

Not Applicable

Completed

Conditions: Early Breast Cancer

Interventions: Behavioral: Activity program
Behavioral: Control

First Posted Date: 2018-12-24

Last Posted Date: 2023-06-27

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 375

Registration Number: NCT03786198

Locations: 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Hirslanden Brustzentrum Bern Biel, Bern, Switzerland
🇨🇭
Tumorzentrum ZeTuP Chur, Chur, Switzerland

and more 29 locations

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Phase 2

Terminated

Conditions: Squamous-cell Non-small Cell Lung Cancer

Interventions: Drug: Rogaratinib

First Posted Date: 2018-12-03

Last Posted Date: 2022-11-09

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 15

Registration Number: NCT03762122

Locations: 🇨🇭
Universitaetsspital Basel, Basel, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭
Kantonsspital Baselland Bruderholz, Bruderholz, Switzerland

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy